Bahamas - Press Releases

MEDIA ADVISORY FOR MARCH 26, 2025

TROY, Mich., March 21, 2025 /PRNewswire/ --Residential Hospice, Michigan, a division of Graham Healthcare Group, will join Reed-Raymond VFW Post 2272 in Durand MI on Friday, March 28 at 11:00 a.m. to honor local Vietnam War Veterans. Veterans will receive an honorary lapel pin, a Certificate of Honor, and a 21-gun salute.

2025321 // -- 2025315""Seen Health""PACE""

Nearly 40,000 customers receive monthly bill discount based on enrollment in benefit programs

Nearly 40,000 customers receive monthly bill discount based on enrollment in benefit programs

SARASOTA, Fla., March 21, 2025 /PRNewswire/ --Dental Care Alliance (DCA) is proud to announce that Victoria Garcia, Chief Financial Officer (CFO), has been named to the Board of Directors for Women in DSO.

Girl Scouts Stand Up, Speak Out, and Make a Difference!

Hosted by Norah O'Donnell, Meryl Streep Served as Honorary Chair of the eventMarch 20, 2025 at The Anthem in Washington D.C.

Local Nurse Entrepreneur Steps Up to Meet the Growing Senior Care Needs Throughout Utah

SEATTLE, March 21, 2025 /PRNewswire/ --

SEATTLE, 21 de marzo de 2025 /PRNewswire-HISPANIC PR WIRE/ --

SEATTLE, March 21, 2025 /PRNewswire-HISPANIC PR WIRE/--

NEW YORK, March 21, 2025 /PRNewswire/ -- IJC denounces the end of federal funding for the Unaccompanied Children Program, which provides legal representation to unaccompanied children in immigration proceedings. The program affects over 90 legal service providers, including IJC, who represent over 26,000 unaccompanied children across the United States.

MIAMI, March 21, 2025 /PRNewswire/ -- Mass tort and personal injury law firm, Rubenstein Law, proudly announces that Partner Miriam Fresco Agrait has been appointed by the Honorable M. Casey Rodgers of the United States District Court for Norther District of Florida to the Data Administration Steering Subcommittee in the ongoing Depo-Provera litigation. This prestigious appointment underscores Mrs. Agrait's legal acumen and commitment to justice in complex pharmaceutical litigation.

MIAMI, 21 de marzo de 2025 /PRNewswire-HISPANIC PR WIRE/ -- El bufete de abogados de agravios masivos y lesiones personales, Rubenstein Law, anuncia con orgullo que la socia Miriam Fresco Agrait ha sido nombrada por el Honorable M. Casey Rodgers del Tribunal de Distrito de los Estados Unidos para el Distrito Norte de Florida para el Subcomit Directivo de Administracin de Datos en el litigio en curso de Depo-Provera. Este prestigioso nombramiento subraya la perspicacia legal y el compromiso con la justicia de la Sra. Agrait en litigios farmacuticos complejos.

SEATTLE, March 23, 2025 /PRNewswire/ --The surge in online supplement sales has led to a troubling rise in counterfeit products infiltrating e-commerce platforms, deceiving buyers with misleading packaging and false advertising. Mitolyn, Bioventra's brand, a well-established name in health and wellness, is issuing a consumer warning regarding unauthorized resellers distributing imitation versions of its product. The company has identified multiple fraudulent listings across online marketplaces, raising concerns about product authenticity and customer safety.

138 fourth-year NEOMED medical students have been matched with prestigious healthcare institutions in Ohio and throughout the U.S.

SHANGHAI, March 23, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for EVM14, a Tumor-Associated Antigen (TAA) vaccine. EVM14 is Everest's first internally developed mRNA therapeutic vaccine to receive FDA IND approval, marking a significant milestone in the Company's efforts to develop innovative mRNA therapeutics in oncology.

-- U.S.IND clearance and revaccination trial initiation supports the differentiated global opportunity for Clover's RSV PreF vaccine (SCB-1019) utilizing validated Trimer-Tag platform --

SAN FRANCISCO andSUZHOU, China, March 23, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that the first participant has been successfully dosed with IBI354 (HER2 Monoclonal Antibody-Camptothecin Derivative Conjugate, HER2 ADC) in a randomized, controlled, multicenter Phase 3 clinical trial (HeriCare-Ovarian01), for platinum-resistant ovarian cancer (PROC) with HER2 expression.

SUZHOU, China, March 23, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer therapies, today announced the submission of aType II variation applicationto the European Medicines Agency (EMA) forsugemalimab. The application seeks approval for the treatment ofpatients with unresectable stage III non-small cell lung cancer (NSCLC) who have not progressed following concurrent or sequential platinum-based chemoradiotherapy (CRT). This marks CStone's second regulatory submission for sugemalimab to the EMA, following its initial approval in Europe for metastatic squamous and non-squamous NSCLC in 2024. If this new indication is approved, sugemalimab would address a critical unmet need in stage III NSCLC, where only one PD-L1 antibody is currently approved in Europe. The drug's dual utility in stage III and IV NSCLC could solidify its role as a cornerstoneimmunotherapy in lung cancer.

SHANGHAI, March 23, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has received 2025 CDMO Leadership Awards in the "Biologics - Global" category. It has also been recognized for excellence in "Best Scientific Expertise", "Best Seamless Delivery Across Phases", "Best Innovative Approach to Technology and Process Execution", making it the most lauded company in the ceremony.

Achieves International Recognition with HIMSS Award for Excellence in Smart Healthcare

HONG KONG, March 23, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, announced on March 21st, 2025 its financial results for fiscal year 2024, reporting total revenue of RMB 2.7 billion, representing an 11.2% year-over-year increase. Notably, the company's adjusted net profit reached RMB 17.2 million, a significant 139% growth compared to 2023, driven by ongoing technology enhancements and improvements in operating efficiency.

BOSTON, March 23, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has agreed to sell an aggregate of 10,250,000 shares of its common stock and warrants to purchase up to 10,250,000 shares of common stock priced at-the-market under Nasdaq rules, at a purchase price of $0.98 per share and associated warrant. The warrants will have an exercise price of $0.86 per share and will be immediately exercisable upon issuance for a period of five years following the date of issuance. All of the shares of common stock and associated warrants are being offered by the Company. The offering is expected to close on March 25, 2025, subject to satisfaction of customary closing conditions.